The Technical AnalystExchange: STO Sector: Healthcare Industry: Biotechnology
Cyxone AB (publ) Price, Forecast, Insider, Ratings, Fundamentals & Signals
17.77% SEK0.143
America/New_York / 17 mai 2024 @ 11:20
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 14.03 mill |
| EPS: | -0.180 |
| P/E: | -0.790 |
| Earnings Date: | May 13, 2024 |
| SharesOutstanding: | 98.44 mill |
| Avg Daily Volume: | 0.585 mill |
| RATING 2024-05-17 |
|---|
| C- |
| Strong Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Strong Sell | |
| DE: | Sell | |
| P/E: | Neutral | |
| Price To Book: | Strong Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | |||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.790 | sector: PE 19.76 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0.00x |
| Company: PE -0.790 | industry: PE 491.84 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
SEK-0.0652 (-145.76%) SEK-0.208 |
| Date: 2024-05-18 |
| Expected Trading Range (DAY) |
|---|
|
SEK 0.133 - 0.153 ( +/- 7.02%) |
| ATR Model: 14 days |
Live Trading Signals (every 1 min)
10.00
Buy
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | SEK0.143 (17.77% ) |
| Volume | 1.478 mill |
| Avg. Vol. | 0.585 mill |
| % of Avg. Vol | 252.64 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For CYXO.ST
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
CYXO.ST
Cyxone AB (publ), a clinical biotech company, develops disease modifying therapies for rheumatoid arthritis, multiple sclerosis, and treatments for virally induced acute respiratory disorders. Its development portfolio comprises Rabeximod in a clinical Phase II program for rheumatoid arthritis and Covid-19 infections; and T20K, a Phase 1 candidate drug for the treatment of multiple sclerosis. The company was incorporated in 2015 and is based in Malmö, Sweden.